iSpecimen (ISPC) Stock Price, News & Analysis

Company Overview

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

Key Stats

• Today's Range: $4.14 to $4.90
• 50-Day Range: $0.19 to $6.30
• 52-Week Range: $3.41 to $12.59
• Volume: 663,353 shs
• Average Volume: 197,397 shs
• Market Capitalization: $4.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

iSpecimen Stock Analysis - MarketRank™

iSpecimen scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for iSpecimen.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of iSpecimen is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of iSpecimen is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

iSpecimen has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.44% of the float of iSpecimen has been sold short.

Short Interest Ratio / Days to Cover

iSpecimen has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in iSpecimen has recently increased by 390.48%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iSpecimen does not currently pay a dividend.

Dividend Growth

iSpecimen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.44% of the float of iSpecimen has been sold short.

Short Interest Ratio / Days to Cover

iSpecimen has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in iSpecimen has recently increased by 390.48%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.30

News Sentiment

iSpecimen has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for iSpecimen this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for ISPC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added iSpecimen to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iSpecimen insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.20% of the stock of iSpecimen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 13.62% of the stock of iSpecimen is held by institutions.

ISPC Stock Analysis - Frequently Asked Questions

How have ISPC shares performed this year?

iSpecimen's stock was trading at $0.5006 at the start of the year. Since then, ISPC stock has increased by 739.0% and is now trading at $4.20.
View the best growth stocks for 2024 here.

How were iSpecimen's earnings last quarter?

iSpecimen Inc. (NASDAQ:ISPC) released its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.09. The company earned $2.86 million during the quarter. iSpecimen had a negative net margin of 91.66% and a negative trailing twelve-month return on equity of 139.25%.

When did iSpecimen IPO?

iSpecimen (ISPC) raised $20 million in an IPO on Thursday, June 17th 2021. The company issued 2,200,000 shares at a price of $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

How do I buy shares of iSpecimen?

Shares of ISPC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of iSpecimen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iSpecimen investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and Braze (BRZE).

Company Calendar

• Last Earnings: 8/06/2024
• Today: 11/16/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/12/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Commercial physical research
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:ISPC
• CUSIP: N/A
• CIK: 1558569
• Web: ispecimen.com
• Phone: 781-301-6700
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($19.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-11,100,000.00
• Net Margins: -91.66%
• Pretax Margin: -91.65%
• Return on Equity: -139.25%
• Return on Assets: -73.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.74
• Quick Ratio: 0.74

Sales & Book Value

• Annual Sales: $10.39 million
• Price / Sales: 0.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.90 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 963,000
• Free Float: 846,000
• Market Cap: $4.04 million
• Optionable: Not Optionable
• Beta: 1.59